Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AMMS-CanSino to Start Clinical Trial of China Ebola Vaccine

publication date: Dec 19, 2014
A China-discovered Ebola vaccine, developed jointly by the Bioengineering Institute of China's Academy of Military Medical Sciences (AMMS) and Tianjin CanSino Biotechnology, has been approved to begin clinical trials. The Bioengineering Institute has been at work on an Ebola vaccine since 2006. After the 2014 outbreak, the research team updated the virus strain to the Zaire-Guinea type currently prevalent in West Africa. To accelerate development of the vaccine, the Institute collaborated with CanSino and the National Institutes for Food and Drug Control. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital